MX2022008068A - Compuesto para el tratamiento y prevención de trastornos del sistema nervioso central. - Google Patents
Compuesto para el tratamiento y prevención de trastornos del sistema nervioso central.Info
- Publication number
- MX2022008068A MX2022008068A MX2022008068A MX2022008068A MX2022008068A MX 2022008068 A MX2022008068 A MX 2022008068A MX 2022008068 A MX2022008068 A MX 2022008068A MX 2022008068 A MX2022008068 A MX 2022008068A MX 2022008068 A MX2022008068 A MX 2022008068A
- Authority
- MX
- Mexico
- Prior art keywords
- prevention
- compound
- treatment
- nervous system
- central nervous
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica para su uso en el tratamiento y/o prevención de un trastorno del sistema nervioso central, que comprende un compuesto de la Fórmula (I): (VER FORMULA) (I) o cualquier sal, derivado, isótopo o mezcla del mismo, y al menos un excipiente farmacéuticamente aceptable.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962955502P | 2019-12-31 | 2019-12-31 | |
| PCT/EP2020/088071 WO2021136827A1 (en) | 2019-12-31 | 2020-12-31 | Compound for the treatment and prevention of central nervous system disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022008068A true MX2022008068A (es) | 2022-09-19 |
Family
ID=74187253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022008068A MX2022008068A (es) | 2019-12-31 | 2020-12-31 | Compuesto para el tratamiento y prevención de trastornos del sistema nervioso central. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230057133A1 (es) |
| EP (1) | EP4084793A1 (es) |
| JP (1) | JP2023510173A (es) |
| CN (2) | CN120983430A (es) |
| AU (1) | AU2020416623A1 (es) |
| BR (1) | BR112022012766A2 (es) |
| CA (1) | CA3166310A1 (es) |
| IL (1) | IL294274A (es) |
| MX (1) | MX2022008068A (es) |
| WO (1) | WO2021136827A1 (es) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2463833B (en) * | 2007-06-26 | 2012-02-08 | Parkinson S Inst | Compositions that prevent or reverse alpha-synuclein fibrillation for use in the treatment of neurological disorders |
-
2020
- 2020-12-31 JP JP2022540355A patent/JP2023510173A/ja active Pending
- 2020-12-31 EP EP20842587.6A patent/EP4084793A1/en active Pending
- 2020-12-31 AU AU2020416623A patent/AU2020416623A1/en active Pending
- 2020-12-31 MX MX2022008068A patent/MX2022008068A/es unknown
- 2020-12-31 CN CN202511035586.XA patent/CN120983430A/zh active Pending
- 2020-12-31 CN CN202080096672.0A patent/CN115103675B/zh active Active
- 2020-12-31 US US17/789,876 patent/US20230057133A1/en not_active Abandoned
- 2020-12-31 IL IL294274A patent/IL294274A/en unknown
- 2020-12-31 WO PCT/EP2020/088071 patent/WO2021136827A1/en not_active Ceased
- 2020-12-31 CA CA3166310A patent/CA3166310A1/en active Pending
- 2020-12-31 BR BR112022012766A patent/BR112022012766A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021136827A1 (en) | 2021-07-08 |
| AU2020416623A1 (en) | 2022-07-14 |
| CN120983430A (zh) | 2025-11-21 |
| CA3166310A1 (en) | 2021-07-08 |
| JP2023510173A (ja) | 2023-03-13 |
| BR112022012766A2 (pt) | 2022-09-06 |
| US20230057133A1 (en) | 2023-02-23 |
| IL294274A (en) | 2022-08-01 |
| EP4084793A1 (en) | 2022-11-09 |
| CN115103675A (zh) | 2022-09-23 |
| CN115103675B (zh) | 2025-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| GEP20257823B (en) | Amino quinazoline derivatives as p2x3 inhibitors | |
| PH12018500147A1 (en) | Benzodiazepine derivatives as rsv inhibitors | |
| MY188700A (en) | Bicyclic ketone sulfonamide compounds | |
| PH12021551541A1 (en) | Compositions and methods for treating neurodegenerative disorders | |
| PH12021550554A1 (en) | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors | |
| SG10201907289VA (en) | Monomethylfumarate prodrug compositions | |
| MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
| MX2020007985A (es) | Inhibicion del canal ionico receptor de potencial transitorio a1. | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| MX2021005967A (es) | Formas purificadas de rofecoxib, métodos de fabricación y uso. | |
| MX2020008498A (es) | Derivados de sobetirome. | |
| TN2022000092A1 (en) | Oral complement factor d inhibitors | |
| TN2018000214A1 (en) | Alkyl dihydroquinoline sulfonamide compounds | |
| PH12018500469A1 (en) | Sulfonamide compounds as voltage-gated sodium channel modulators | |
| MX2021003508A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
| MX2021003901A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
| ZA202204907B (en) | Orally disintegrating pharmaceutical compositions of apixaban | |
| MX2019000413A (es) | Inhibidores de triptofano 2,3-dioxigenasa. | |
| MY199104A (en) | Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder | |
| PH12017501736A1 (en) | Indole derivatives | |
| MX2022008068A (es) | Compuesto para el tratamiento y prevención de trastornos del sistema nervioso central. | |
| MX2024003930A (es) | Moduladores de trpml, sus composiciones y metodos de uso. | |
| PH12022550895A1 (en) | Compositions for preventing or treating chronic obstructive pulmonary diseases (copd) |